Physician profile
Sara Brown
NPI 1902823909
$7,129.15
in general payments reported to CMS, 2019-2025
26 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,659 · 2022: $2,535 · 2023: $707 · 2024: $229.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $935.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $935.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,156.33 | 2021-2023 | Arexvy |
| Janssen Pharmaceuticals, INC | $844.71 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $672.96 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $650.51 | 2021-2024 | Jardiance |
| Novo Nordisk INC | $648.15 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $447.44 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $364.79 | 2021-2022 | |
| Lilly USA, LLC | $330.30 | 2022-2024 | Jardiance |
| Amgen INC. | $321.85 | 2023 | Otezla, Repatha |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $257.80 | 2022 | |
| Abbvie INC. | $232.45 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $203.04 | 2022 | |
| Abbott Laboratories | $163.27 | 2021-2023 | Freestyle Libre 3 |
| Bayer Healthcare Pharmaceuticals INC. | $161.10 | 2022 | |
| Pfizer INC. | $149.01 | 2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $108.91 | 2021-2022 | |
| Allergan, INC. | $107.63 | 2022 | |
| Novartis Pharmaceuticals Corporation | $96.16 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $59.22 | 2021-2022 | |
| Amarin Pharma, INC. | $35.17 | 2021 | |
| Janssen Biotech, INC. | $22.13 | 2023 | Tremfya |
| Astellas Pharma US INC | $21.83 | 2021 | |
| Nestle Healthcare Nutrition INC. | $21.25 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $19.00 | 2021 | |
| Xeris Pharmaceuticals, INC. | $17.15 | 2022 | |
| Paratek Pharmaceuticals, INC. | $16.99 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sara Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.